Table 1 Clinical characteristics and marker expression of the study population
From: Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization
Case | Age | pT | pN | Gleason score | PSA pre-surgery | % positive tumor cells by PCA3 chromogenic method | % positive tumor cells by PCA3 radioactive method |
|---|---|---|---|---|---|---|---|
1 | 53 | 2b | 0 | 6 | 9.7 | 100 | 80 |
2 | 59 | 2c | 0 | 7 | 11 | 0 | 0 |
3 | 65 | 3b | 1 | 9 | 6 | 90 | 90 |
4 | 64 | 2c | 0 | 7 | NA | 90 | 90 |
5 | 65 | 3a | 0 | 6 | 10 | 80 | 100 |
6 | 66 | 2c | 0 | 7 | 4.6 | 90 | 90 |
7 | 64 | 3a | 0 | 7 | 8.8 | 75 | 75 |
8 | 63 | 3a | 0 | 7 | 9.9 | ND | 100 |
9 | 57 | 2c | 0 | 6 | 17 | 25 | 100 |
10 | 71 | 3a | 0 | 9 | 9.7 | 90 | 90 |
11 | 56 | 2b | 0 | 9 | 6.9 | ND | 90 |
12 | 75 | 2c | 0 | 6 | 5.6 | 5 | 50 |
13 | 71 | 2c | 0 | 5 | 14 | 75 | 75 |
14 | 53 | 3a | 1 | 7 | 56 | 90 | 20 |
15 | 59 | 2b | 0 | 6 | 3.1 | 100 | 100 |
16 | 86 | 2b | 0 | 7 | 5 | 75 | 100 |
17 | 58 | 3b | 1 | 7 | 3.6 | 80 | 75 |
18 | 70 | 2c | 0 | 6 | 2.8 | 60 | 75 |
19 | 69 | 3a | 1 | 7 | 25 | 15 | 10 |
20 | 61 | 2c | 0 | 7 | 60 | 75 | 90 |
21 | 66 | 2c | 0 | 7 | 11 | 75 | 20 |
22 | 66 | 3a | 0 | 8 | 0 | 25 | 30 |
23 | 66 | 3a | 0 | 7 | 4 | 0 | 0 |
24 | 66 | 3a | 0 | 8 | NA | 5 | 10 |
25 | 56 | 2c | 0 | 7 | 6.8 | 5 | 10 |
26 | 64 | 2b | 0 | 7 | 11 | ND | 75 |
27 | 66 | 3a | 0 | 6 | NA | ND | 90 |
28 | 53 | 2c | 0 | 7 | 11 | 5 | 10 |
